Last €76.00 EUR
Change Today +0.23 / 0.30%
Volume 2.0K
As of 10:25 AM 07/14/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax:

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of healthcare products. The company has a commercial presence in approximately 100 countries, and its products are available in approximately 170 countries. Principal Activities The company’s activities are organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. In parallel, the company operates through seven growth platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. Pharmaceuticals In the Pharmaceuticals activity, the company’s major product categories are as follows: Diabetes Solutions: Its main products are Lantus, a long-acting analog of human insulin; Amaryl, an oral once-daily sulfonylurea; Apidra, a rapid-acting analog of human insulin; Insuman, a range of human insulin solutions and suspensions; Lyxumia, a once-daily prandial GLP-1 receptor agonist; and BGStar, iBGStar and MyStar Extra, blood glucose meters. Rare Diseases: Its principal products are enzyme replacement therapies: Cerezyme to treat Gaucher disease; Myozyme/Lumizyme to treat Pompe disease; Fabrazyme to treat Fabry disease; and Aldurazyme to treat mucopolysaccharidosis Type I (MPS I). Multiple sclerosis (MS): Its MS franchise consists of Aubagio- a once daily, oral immunomodulator and Lemtrada, a humanized monoclonal antibody that selectively targets CD52. Both products have been developed to treat patients with relapsing forms of MS. Rare Diseases and MS are the therapeutic areas of the ‘Genzyme’ growth platform. Oncology: Its products include Taxotere, a taxane derivative representing a cornerstone therapy in several cancer types; Jevtana, a taxane derivative, indicated for patients with prostate cancer; Eloxatin, a platinum agent, which is a key treatment for colorectal cancer; Thymoglobulin, a broad immuno-suppressive and immuno-modulating agent; Mozobil, a hematopoietic stem cell mobilizer for patients with hematologic maligancies; and Zaltrap, a recombinant fusion protein, indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. Other prescription products: Its thrombosis medicines include Plavix, an anti-platelet agent indicated for a number of atherothrombotic conditions, and Lovenox, a low molecular weight heparin indicated for prevention and treatment of deep vein thrombosis and for unstable angina and myocardial infarction. The company’s cardiovascular medicines include Multaq, an anti-arrhythmic agent, and Aprovel/CoAprovel, two hypertension treatments. The company’s renal business includes Renagel/Renvela, oral phosphate binders used in patients with chronic kidney disease (CKD) on dialysis to treat high phosphorus levels. The company’s biosurgery business includes Synvisc and Synvisc-One, viscosupplements used to treat pain associated with osteoarthritis of certain joints. The company’s global pharmaceutical portfolio also includes a range of products in Consumer Health Care (CHC). Human Vaccines The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. It offers vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Animal Health The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers a complete range of medicines and vaccines for a wide variety of animal species. Merial is an animal healthcare company, focused in the research, development, manufacture and delivery of pharmaceuticals and vaccines used by veterinarians, farmers and pet owners and providing a line of products to enhance the health, well-being and performance of a range of production and companion animals. Sales and Marketing The company’s vaccines are sold and distributed thr

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNW:GR €76.00 EUR +0.23

SNW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.45 USD -0.51
Amgen Inc $119.64 USD -0.13
Bayer AG €101.55 EUR +0.34
Gilead Sciences Inc $89.66 USD +0.93
Novo Nordisk A/S kr251.50 DKK +3.70
View Industry Companies
 

Industry Analysis

SNW

Industry Average

Valuation SNW Industry Range
Price/Earnings 26.3x
Price/Sales 3.0x
Price/Book 1.7x
Price/Cash Flow 14.9x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.